Design, Synthesis and Interaction at the Vesicular Monoamine Transporter-2 of Lobeline Analogs: Potential Pharmacotherapies for the Treatment of Psychostimulant Abuse

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|11|9|1103-1127

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.11, Iss.9, 2011-05, pp. : 1103-1127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2

By Rehavi M.   Roz N.   Weizman A.  

European Neuropsychopharmacology, Vol. 12, Iss. 3, 2002-06 ,pp. : 261-268

Elsevier

Access to resources Recommend Favorite

The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases

By  

Medicinal Chemistry, Vol. 11, Iss. 2, 2015-01 ,pp. : 104-108

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of psychostimulants on vesicular monoamine transporter function

By Fleckenstein A.E.   Hanson G.R.  

European Journal of Pharmacology, Vol. 479, Iss. 1, 2003-10 ,pp. : 283-289

Elsevier

Access to resources Recommend Favorite

Binding of -dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific

By Kilbourn M.   Lee L.   Borght T.V.   Jewett D.   Frey K.  

European Journal of Pharmacology, Vol. 278, Iss. 3, 1995-05 ,pp. : 249-252

Elsevier

Access to resources Recommend Favorite

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments

By Borght T.V.   Kilbourn M.   Desmond T.   Kuhl D.   Frey K.  

European Journal of Pharmacology, Vol. 294, Iss. 2, 1995-12 ,pp. : 577-583

Elsevier

Access to resources Recommend Favorite